Artefill May Be Effective Treatment Option for Facial Lipoatrophy
Posted by Cosmetic Surgery Review on March 2, 2010
Artefill is among the leading dermal fillers on the market to treat lines and wrinkles, and is currently available at many medical spas, cosmetic surgery centers and plastic surgery centers around the country.
The injectable was recently part of two clinical studies to determine if it would be effective as a long-term treatment for facial lipoatrophy. Results of the study were presented at the Advances in Cosmetic and Medical Dermatology’s Maui Derm 2010” meeting in Hawaii in late January, and at the American Academy of Cosmetic Dermatology Scientific Meeting in Orlando, Florida later that month.
The soft tissue filler is currently used to treat nasolabial folds, reduce lines and wrinkles around the cheeks and forehead, and can be part of a “liquid facelift” procedure. The study evaluated the efficacy of Artefill for thecorrection of lipoatrophy in HIV patients. Patients received injections over a six-month period until full correction was achieved, and were monitored shortly after the injection was administered to determine if any muscle atrophy occurred.
According to Dr. Joseph Eviatar, FACS of Chelsea Eye and Cosmetic Surgery Associates who presented at the AACS Scientific Meeting, “Artefill proved to be effective in restoring volume to the face in these HIV lipoatrophy patients and we believe may offer a more long-term, cost effective treatment option for the patient population.”
In another session presented at the Maui Derm 2010 conference, doctors reported that Artefill was effective in treating all HIV lipoatrophy patients and improvement ranged between 50 to 100 percent. Non-HIV patients also experienced a significant improvement in the overall contours of the face.
Dr. Farhad Niroomand, Associate Clinical Professor of Dermatology who presented at the Maui conference, also stated that he believes Artefill is a viable treatment option for non-surgical anti-aging enhancement, and is a viable treatment option for patients with lipoatrophy. (Source: MedicalNewsToday.com)